Literature DB >> 31784873

Treating Persistent Pain After Breast Cancer Surgery.

James S Khan1,2, Karim S Ladha2,3, Faraj Abdallah4, Hance Clarke5,6,7.   

Abstract

Breast cancer is one of the most commonly diagnosed cancers among women, and since the prognosis of breast cancer has substantially improved in past decades, complications of management are becoming increasingly apparent. Persistent pain lasting greater than 3 months after breast cancer surgery is unfortunately a common complication affecting approximately 30% of patients after tumour resection. Persistent breast cancer pain has neuropathic features and is typically mild-to-moderate in intensity, with approximately 10% suffering from severe pain. There is an increasing need to prevent persistent pain through the use of transitional pain programmes and perioperative interventions, and to identify novel treatment modalities to reduce suffering in those who unfortunately develop persistent pain. This review serves to provide an overview on persistent pain after breast cancer surgery, its pathophysiology, and current management strategies.

Entities:  

Mesh:

Year:  2020        PMID: 31784873     DOI: 10.1007/s40265-019-01227-5

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  82 in total

Review 1.  Neuropathic pain following breast cancer surgery: proposed classification and research update.

Authors:  Beth F Jung; Gretchen M Ahrendt; Anne Louise Oaklander; Robert H Dworkin
Journal:  Pain       Date:  2003-07       Impact factor: 6.961

2.  Coping, catastrophizing and chronic pain in breast cancer.

Authors:  Scott R Bishop; David Warr
Journal:  J Behav Med       Date:  2003-06

Review 3.  The efficacy of pain neuroscience education on musculoskeletal pain: A systematic review of the literature.

Authors:  Adriaan Louw; Kory Zimney; Emilio J Puentedura; Ina Diener
Journal:  Physiother Theory Pract       Date:  2016-06-28       Impact factor: 2.279

4.  Radiofrequency treatment of the thoracic paravertebral nerve combined with glucocorticoid for refractory neuropathic pain following breast cancer surgery.

Authors:  Ken-ichiro Uchida
Journal:  Pain Physician       Date:  2009 Jul-Aug       Impact factor: 4.965

5.  Granular cell traumatic neuroma: a lesion occurring in mastectomy scars.

Authors:  R Rosso; M Scelsi; L Carnevali
Journal:  Arch Pathol Lab Med       Date:  2000-05       Impact factor: 5.534

6.  EMLA reduces acute and chronic pain after breast surgery for cancer.

Authors:  A Fassoulaki; C Sarantopoulos; A Melemeni; Q Hogan
Journal:  Reg Anesth Pain Med       Date:  2000 Jul-Aug       Impact factor: 6.288

7.  Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons.

Authors:  P Honore; S D Rogers; M J Schwei; J L Salak-Johnson; N M Luger; M C Sabino; D R Clohisy; P W Mantyh
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

8.  Prevalence of and factors associated with persistent pain following breast cancer surgery.

Authors:  Rune Gärtner; Maj-Britt Jensen; Jeanette Nielsen; Marianne Ewertz; Niels Kroman; Henrik Kehlet
Journal:  JAMA       Date:  2009-11-11       Impact factor: 56.272

Review 9.  Central sensitization: a generator of pain hypersensitivity by central neural plasticity.

Authors:  Alban Latremoliere; Clifford J Woolf
Journal:  J Pain       Date:  2009-09       Impact factor: 5.820

Review 10.  Pharmacotherapy for Neuropathic Pain: A Review.

Authors:  Diego Fornasari
Journal:  Pain Ther       Date:  2017-11-24
View more
  3 in total

1.  Perioperative Inpatient Opioid Consumption Following Autologous Free-Flap Breast Reconstruction Patients: An Examination of Risk and Patient-Reported Outcomes.

Authors:  Jonas A Nelson; Thais O Polanco; Meghana G Shamsunder; Michelle Coriddi; Evan Matros; Madeleine E V Hicks; Joseph J Disa; Babak J Mehrara; Robert J Allen; Joseph H Dayan; Anoushka Afonso
Journal:  Ann Surg Oncol       Date:  2021-05-06       Impact factor: 4.339

2.  Quality of Life Following Receipt of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer.

Authors:  Shoshana M Rosenberg; Anne O'Neill; Karen Sepucha; Kathy D Miller; Chau T Dang; Donald W Northfelt; George W Sledge; Bryan P Schneider; Ann H Partridge
Journal:  JAMA Netw Open       Date:  2022-02-01

Review 3.  Sexual dysfunction as a challenge in treated breast cancer: in-depth analysis and risk assessment to improve individual outcomes.

Authors:  Abraham Hernández-Blanquisett; Valeria Quintero-Carreño; Angelina Álvarez-Londoño; María Cristina Martínez-Ávila; Raissa Diaz-Cáceres
Journal:  Front Oncol       Date:  2022-08-02       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.